Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Touchlight has established itself as a leading provider of synthetic DNA manufacturing using its proprietary dbDNA™ enzymatic process. The company’s technology is used as critical starting material or API for advanced therapies such as mRNA vaccines, viral vectors, cell therapies, and nonviral gene therapies. Multiple client products using dbDNA are already in clinical trials. The company has also partnered with academic institutions on early-stage vaccine development.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Touchlight.